JangoBio
June 22, 2026
Theater 1
Type: Company Presentation
Focus Area:
Regenerative Medicine
JangoBio is a regenerative medicine company developing stem cell–based therapies to treat diseases of aging and extend healthy longevity. Its pipeline is led by Jango-Renew, an advanced stem cell therapy for osteoarthritis, currently progressing toward FDA approval. The company’s second pipeline is a hormone-producing organoid therapy that restores sex hormone balance and mitigates diseases of aging. This product has been demonstrated to significantly extend longevity in an aging rodent model. In parallel, its CDMO subsidiary, JangoCell, provides large-scale biomanufacturing of stem cell lines and other services for external partners.
Company HQ City:
Fitchburg
Company HQ State:
Wisconsin
Company HQ Country:
United States
Year Founded:
2015
Lead Product in Development:
Jango-Renew - canine and human osteoarthritis
CEO
Craig S. Atwood, Ph.D.
Development Phase of Lead Product
Pre-Clinical
When you expect your next catalyst update?
April 2027
What is your next catalyst (value inflection) update?
Completion of pilot study for INAD application.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}